摘要:
The invention relates to a method for transferring alkylidene groups to organic compounds. According to the inventive method, at least one organic compound in a liquid or dissolved from is mixed with at least one alkylidene group transfer reagent in a liquid or dissolved form in at least one microreactor, reacted during a specific reaction time and the olefin thus obtained is, optionally, isolated from the reaction mixture.
摘要:
The invention relates to a method for producing indols, characterized in that at least one aryl hydrazone in liquid or dissolved form is mixed with at least one catalyst in liquid or dissolved form in an optionally temperable microreactor and reacted for a residence time, before the resulting indol compound is optionally isolated from the reaction mixture.
摘要:
The invention relates to a method for the 1,3 dipolar cycloaddition of organic compounds, characterised in that the reaction is carried out in a microreactor.
摘要:
The invention relates to a method for oximating organic carbonyl compounds and/or CH-acid compounds, wherein at least one organic carbonyl compound and/or CH-acid compound in a liquid or dissolved form is mixed with at least one oximating agent in a liquid or dissolved form in at least one microreactor, is reacted during a residence time and the organic oxime thus formed is optionally isolated from the reaction mixture.
摘要:
The invention relates to a novel method for the nitration of organic compounds, preferably of aromatics and heteroaromatics, using known and novel types of nitration reagents.
摘要:
The invention relates to novel compounds of formula (I), wherein R, R?1, R2, R3¿, n and p have the meaning defined in claim 1. Said compounds are inhibitors of clotting factor Xa and can be used for the prophylaxis and/or therapy of thrombo-embolic disorders.
摘要:
The invention relates to novel compounds of formula (I), wherein X, Y, R, R?1, R2, R3¿ and n have the meaning cited in patent claim 1. Said compounds are inhibitors of coagulation factor Xa and can be used in the prophylaxis and/or therapy of thromboembolic diseases.